{"id":550086,"date":"2021-06-28T21:50:01","date_gmt":"2021-06-28T21:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=550086"},"modified":"2021-06-28T21:50:01","modified_gmt":"2021-06-28T21:50:01","slug":"diabetic-kidney-disease-pipeline-analysis-new-therapies-to-come-for-diabetic-kidney-disease-are-expected-to-boost-the-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-kidney-disease-pipeline-analysis-new-therapies-to-come-for-diabetic-kidney-disease-are-expected-to-boost-the-treatment-landscape_550086.html","title":{"rendered":"Diabetic Kidney Disease Pipeline Analysis: New therapies to come for Diabetic Kidney Disease are expected to boost the treatment landscape"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1624864396.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Diabetic Kidney Disease Pipeline Analysis: New therapies to come for Diabetic Kidney Disease are expected to boost the treatment landscape\" src=\"https:\/\/www.abnewswire.com\/uploads\/1624864396.png\" alt=\"Diabetic Kidney Disease Pipeline Analysis: New therapies to come for Diabetic Kidney Disease are expected to boost the treatment landscape\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Diabetic Kidney Disease Pipeline <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s Diabetic Kidney Disease pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects in the Diabetic Kidney Disease industry. The disease summary and Diabetic Kidney Disease treatment guidelines are included in a complete description of the Diabetic Kidney Disease pipeline landscape.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/4faf537c7b3581f0f9506528cdf23345.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&#8217;s <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Diabetic Kidney Disease pipeline report<\/a><\/strong><span> provides in-depth analysis of the current clinical development landscape and growth prospects in the Diabetic Kidney Disease industry. The disease summary and Diabetic Kidney Disease treatment guidelines are included in a complete description of the Diabetic Kidney Disease pipeline landscape.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Crucial Findings from the Diabetic Kidney Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Bayer<\/strong><span> announced in January 2021 that the US Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) and granted Priority Review for <\/span><strong>finerenone<\/strong><span> for the treatment of chronic kidney disease (CKD) and type 2 diabetes patients (T2D).<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Diabetic Kidney Disease pipeline drug which is in phase III clinical trials is <\/span><span><strong>Bardoxolone methyl<\/strong>. <\/span><span>While DKD pipeline drug in phase II clinical trials is <\/span><strong>Selonsertib<\/strong><span> along with others.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Some DKD pipeline therapies such as <\/span><span><strong>ORBCEL-M<\/strong>, <\/span><span>and others are in the phase I\/II of DKD clinical trials.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Key players in Diabetic Kidney Disease pipeline landscape include <\/span><strong>Bayer, Reata Pharmaceuticals, Gilead Sciences, Orbsen Therapeutics, Dimerix, CSL Behring, <\/strong><span>and others.&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>To learn more, request sample @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chronic Kidney Disease Pipeline Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Diabetic Kidney Disease: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Diabetic Kidney Disease (DKD)<\/strong> also known as, Diabetic Nephropathy, is a chronic, progressive disease that develops over time. Diabetic nephropathy is a serious long-term complication that affects about 30% of people with type 1 diabetes (T1D) and 40% of people with type 2 diabetes (T2D). DKD is also linked to a high rate of mortality.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Diabetic Kidney Disease: Symptoms<\/strong>&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Fatigue, anorexia, and swelling of the limbs are common signs of Diabetic Kidney Disease (DKD), which may go unnoticed until the disease is advanced.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Diabetic Kidney Disease: Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The main goal of treatment is to delay or stop the progression of ESRD. Glycemic and blood pressure control have long been the pillars of treatment, with dietary therapy being a less well-established strategy. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are more efficient in slowing DKD progression.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Diabetic Kidney Disease Pipeline Analysis: Drug Profiles<\/strong>&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Finerenone: Bayer<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Product Description<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA). Finerenone&#8217;s marketing authorization application (MAA) for the treatment of chronic kidney disease (CKD) and type 2 diabetes (T2D) has been submitted to the European Medicines Agency (EMA), and the new drug application (NDA) has been accepted by the United States Food and Drug Administration (FDA).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phase III<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>NCT02540993: <\/strong><span>Bayer began a randomised, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study in September 2015 to see if oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes and diabetic kidney disease (FIGARO-DKD).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get in touch to know more about the <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Diabetic Kidney Disease Pipeline Therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Diabetic Kidney Disease Pipeline Therapies and Key Companies<\/strong>&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Finerenone: Bayer<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Bardoxolone methyl: Reata Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Selonsertib: Gilead Sciences<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>ORBCEL-M: Orbsen Therapeutics<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Diabetic Kidney Disease <\/strong><span><strong>Therapeutics Assessment<\/strong>&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Product Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Monotherapy<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Combination Therapy<\/span><\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Stage<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Discovery<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pre-Clinical<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Phase I<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Phase II<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Phase III<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pre-registration<\/span><\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Route of Administration<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Inhalation<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Intravenous<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Oral<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Subcutaneous<\/span><\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Molecule Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Small Molecule<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Stem Cell Therapy<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Gene Therapy<\/span><\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Targets<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Immune System<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Multiple Kinase<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Protease<\/span><\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Mechanism of Action<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Protease Inhibitors<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Immunomodulatory<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Multiple Kinase Inhibitors<\/span><\/p>\n<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong><span> Global<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Diabetic Kidney Disease Key Players: <\/strong><span>Bayer, Reata Pharmaceuticals, Gilead Sciences, Orbsen Therapeutics, Dimerix, CSL Behring, among others<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Diabetic Kidney Disease Pipeline Therapies: <\/strong><span>Finerenone, Bardoxolone methyl, Selonsertib, ORBCEL-M, and others<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Table of Contents<\/strong>&nbsp;<\/span><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"83\" \/>\n<col width=\"541\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Diabetic Kidney Disease (DKD): Overview<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DKD Pipeline Therapeutics<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DKD Late Stage Products (Pre-registration)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DKD Late Stage Products (Phase&nbsp; III)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DKD Mid Stage Products (Phase&nbsp; II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DKD Early Stage Products (Phase&nbsp; I\/II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DKD Pre-clinical and Discovery Stage Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DKD Therapeutic Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DKD Inactive Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Diabetic Kidney Disease (DKD)- Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Diabetic Kidney Disease (DKD)- Market Drivers and Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For rich insights into Healthcare and Pharmaceutical News, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key questions answered in the Diabetic Kidney Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>What therapy options are available for Diabetic Kidney Disease?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>How many pharmaceutical companies are working on Diabetic Kidney Disease treatments?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Which of these companies&rsquo; treatments are the most popular?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>What is the total number of Diabetic Kidney Disease medications produced by each company?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>How many Diabetic Kidney Disease pipeline medicines are in early, mid, or late development?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>How many of the therapies in development can be used on their own or in combination with other treatments?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>What are the most significant industry-industry and industry-academy collaborations, mergers and acquisitions, and licencing practises that affect Diabetic Kidney Disease?<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-cardiomyopathy-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Diabetic Cardiomyopathy Pipeline Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get comprehensive analysis of <\/span><span>Diabetic Cardiomyopathy<\/span><span> pipeline therapies and key companies including <\/span><strong>Imbria Pharmaceuticals, Applied Therapeutics,<\/strong><span> among others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=diabetic-kidney-disease-pipeline-analysis-new-therapies-to-come-for-diabetic-kidney-disease-are-expected-to-boost-the-treatment-landscape\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=diabetic-kidney-disease-pipeline-analysis-new-therapies-to-come-for-diabetic-kidney-disease-are-expected-to-boost-the-treatment-landscape\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Diabetic Kidney Disease Pipeline DelveInsight&#8217;s Diabetic Kidney Disease pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects in the Diabetic Kidney Disease industry. The disease summary and Diabetic Kidney Disease treatment guidelines are included in &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-kidney-disease-pipeline-analysis-new-therapies-to-come-for-diabetic-kidney-disease-are-expected-to-boost-the-treatment-landscape_550086.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-550086","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=550086"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550086\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=550086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=550086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=550086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}